Director/PDMR Shareholding

RNS Number : 5139Q
Instem plc
19 February 2019
 

Instem plc
("Instem" or the "Company")

Director/PDMR Shareholding

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, was notified on 19 February 2019, that the DG 2008 Discretionary Settlement (of which David Gare,  Company chairman, and his wife are the trustees) transferred 100,000 ordinary shares of 10p each in the Company ("Ordinary Shares") to David's son, Adrian Gare, for nil consideration. Following the transaction, the DG 2008 Discretionary Settlement now has a total interest in 1,158,427 Ordinary Shares, representing approximately 7.28% of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

David Gare and his wife (via the DG 2008 Discretionary Settlement)

 

2

Reason for the notification

a)

 

Position/status

Chairman of the Company

b)

 

Initial notification /Amendment

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

 

Instem plc

b)

 

LEI

 

 

213800PILYUFNNROQX68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 10p each



Identification code

GB00B3TQCK30



b)

 

Nature of the transaction

Transfer of ordinary shares

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




0p

100,000







d)

 

Aggregated information




- Aggregated volume

N/A



- Price




e)

 

Date of the transaction

19 February 2019

f)

Place of the transaction

London Stock Exchange (XLON)

 

For further information, please contact:

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO


Nigel Goldsmith, CFO




 

N+1 Singer (Nominated Adviser & Broker)

 

+44 (0) 20 7496 3000

Richard Lindley

Rachel Hayes




 

Walbrook Financial PR

 

+44 (0) 20 7933 8780

Paul Cornelius

instem@walbrookpr.com

Nick Rome

Sam Allen

 




About Instem 

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

 Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

To learn more about Instem solutions and its mission, please visit instem.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBSGDDLGBBGCC

Companies

Instem (INS)
UK 100